Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP)
نویسندگان
چکیده
منابع مشابه
An update on the thrombotic microangiopathies hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP).
Welcome to this special issue of Seminars in Thrombosis & Hemostasis, which summarizes up-to-date knowledge on pathogenesis, diagnosis, and treatment of thrombotic microangiopathies (TMAs) such as (enterohemorrhagic) E. coli (EHEC)–associated hemolytic uremic syndrome (HUS) (eHUS), atypical HUS (aHUS), (aHUS) and thrombotic thrombocytopenic purpura (TTP). This issue also reviews C3 glomerulopat...
متن کاملThrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13.
Thrombotic microangiopathy (TMA) is a term used to describe a group of disorders characterized by hemolytic anemia (with prominent red blood cell fragmentation), thrombocytopenia, and thrombosis in the microvasculature. It may be used when describing patients with thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome, atypical hemolytic uremic syndrome, as well as a myriad of oth...
متن کاملThrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
Thrombotic microangiopathies (TMAs) are pathological conditions characterized by generalized microvascular occlusion by platelet thrombi, thrombocytopenia, and microangiopathic hemolytic anemia. Two typical phenotypes of TMAs are hemolytic- uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). Other disorders occasionally present with similar manifestations. Depending on whether ...
متن کاملPlasmapheresis in thrombotic thrombocytopenic purpura (TTP)
A 70-year-old woman with thrombotic thrombocytopenic purpura (TTP) was treated with plasmapheresis using fresh frozen plasma as a fluid replacement. Complete recovery and lasting remission were observed. It appears that plasmapheresis combined with massive fresh frozen plasma can be an effective mode of treatment for patients who were, otherwise, refractory to conventional therapy.
متن کاملIpilimumab-induced thrombotic thrombocytopenic purpura (TTP)
BACKGROUND CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) was the first immune checkpoint receptor clinically targeted for use in cancer treatment. It is expressed exclusively on T-cells where its primary role is to regulate the amplitude of the early stages of T-cell activation.1 Ipilimumab, a CTLA-4 blocking antibody, has been widely used for the treatment of patients with high risk and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hematology
سال: 2017
ISSN: 1520-4391,1520-4383
DOI: 10.1182/asheducation-2017.1.632